Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL18544095 | 1.00 | TSHR (0.46) | TSHRALDH1A1TDP1LMNAMAPK1 | |
| Alcohol SCHEMBL2888838 | 0.96 | TSHR (0.43) | TSHRALDH1A1TDP1LMNA | |
| Isopropyl Alcohol SCHEMBL8675755 | 0.93 | TSHR (0.40) | TSHRALDH1A1TDP1LMNA | |
| Isopropyl Alcohol SCHEMBL6672907 | 0.93 | TSHR (0.40) | TSHRALDH1A1TDP1LMNA | |
| Chloroform SCHEMBL7162033 | 0.90 | TSHR (0.38) | TSHRALDH1A1TDP1MAPK1 | |
| Ether SCHEMBL1325841 | 0.87 | ALDH1A1 (0.41) | TSHRALDH1A1LMNA | |
| Propanol SCHEMBL4556972 | 0.86 | ALDH1A1 (0.37) | TSHRALDH1A1TDP1LMNA | |
| Ethylene Glycol SCHEMBL296878 | 0.85 | TSHR (0.39) | TSHRTDP1MAPK1 | |
| Alcohol SCHEMBL4230497 | 0.83 | TSHR (0.38) | TSHRALDH1A1TDP1 | |
| Methyl Alcohol SCHEMBL169224 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230092359-A1 | GEMFIBROZIL FORMULATION | POLARYX THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | claimed |
| CN-115160246-A | Process for recovering valsartan from valsartan mother liquor | 江苏新瑞药业有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-112745268-B | Crystal form of benzimidazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2021-06-24 | — | — | US | claimed |
| CN-112745268-A | Crystal form of benzimidazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2021-05-04 | — | — | CN | claimed |
| EP-3808745-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-04-21 | — | — | EP | claimed |
| CN-111819178-A | Crystal form of pyrazolo heteroaryl derivative hydrochloride and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-10-23 | — | — | CN | claimed |
| CN-109311891-B | Crystals of pyrrolopyrimidine compounds as JAK inhibitors | 正大天晴药业集团股份有限公司 | 2020-09-04 | — | — | CN | claimed |
| CN-110407878-A | Tenofovir prodrug crystal form and its preparation method and application | HANGZHOU HEZE PHARMACEUTICAL TECH CO LTD | 2019-11-05 | — | — | CN | claimed |
| CN-106939002-B | A kind of crystal form and preparation method thereof of BTK kinase inhibitor | 江苏恒瑞医药股份有限公司 | 2019-09-24 | — | — | CN | claimed |
| CN-101906066-A | Method for preparing donepezil hydrochloride crystal form I | ZHEJIANG HUAHAI PHARM CO LTD | 2010-12-08 | — | — | CN | claimed |
| CN-100422148-C | Technology for industrialized production of hydrochloric acid multi-donepezil | TIANJIN INST PHARM RESEARCH (CN) | 2008-10-01 | — | — | CN | claimed |
| US-20080171885-A1 | Process for Preparation of Highly Pure Trandolapril | LUPIN LIMITED (IN) | 2008-07-17 | — | — | US | claimed |
| EP-1866327-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL | Lupin Ltd. (IN) | 2007-12-19 | — | — | EP | claimed |
| CN-1305837-C | Improved prepn process of itopride medicine material | NEW MEDICINE DEV CT JILIN XIUZ (CN) | 2007-03-21 | — | — | CN | claimed |
| CN-1886419-A | Crystalline forms of 3 beta-amino-17-methylene-androstane-6 alpha, 7 beta-diol hydrochloride | INFLAZYME PHARM LTD (CA) | 2006-12-27 | — | — | CN | claimed |
| WO-2006085332-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL | LUPIN LIMITED (IN) | 2006-08-17 | — | — | WO | claimed |
| CN-1706815-A | Improved prepn process of itopride medicine material | NEW MEDICINE DEV CT JILIN XIUZ (CN) | 2005-12-14 | — | — | CN | claimed |
| CN-1524851-A | Technology for industrialized production of hydrochloric acid multi-donepezil | 天津药物研究院 | 2004-09-01 | — | — | CN | claimed |
| US-6518456-B1 | Process for the production and purification of gabapentin, i.e. 1-(aminomethyl)cyclohexyl-acetic acid, which comprises hydrolysis of 2-aza-spiro(4.5)decan-3-one with HCl, treatment of the resulting product and filtration with | PROCOS S.P.A. (IT) | 2003-02-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171885-A1 | Process for Preparation of Highly Pure Trandolapril | TPH1, HTR1A, HTR3A | TSHR 329/4885ALDH1A1 316/4885TDP1 378/4885 |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | CYP2F1, CYP7A1, CYP11B2 | TSHR 2375/4885ALDH1A1 1161/4885TDP1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.